Among a total of 51 CTCs identified in patients with early disease, 19 (37%) were CK/HER2-positive, whereas the respective numbers for patients with metastatic disease were 35 out of 103 cells (34%). This evidence concerns the gene ERBB2 and metastatic neoplasm.